Novartis delivers strong financial performance in second quarter
- Details
- Category: Novartis
Novartis delivered a strong performance in the second quarter of 2010 - with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines - as the Group made progress on its agenda on innovation, growth and productivity.
Bayer Schering Pharma enters strategic partnership with Hospital in China
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People's Liberation Army General Hospital (301 Hospital) in Beijing, China.
FDA Grants Priority Review Designation to Denosumab
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.
Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
- Details
- Category: Financial
Mylan Inc. (Nasdaq: MYL) has announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company for $550 million in cash.
Amgen Foundation and Changemakers Launch Global Online Competition to Empower Patients
- Details
- Category: Amgen
The Amgen Foundation is supporting an online competition with Ashoka's Changemakers to find the best solutions that elevate patients' voices to improve health outcomes globally.
GlaxoSmithKline (GSK) responds to Senate Finance Committee letter
- Details
- Category: GlaxoSmithKline
The Senate Finance Committee (SFC) has released a small subset of the 14 million pages of documents provided to plaintiffs' counsel in the product liability litigation. They include drafts and other documents taken out of context, which therefore are incomplete and misleading.
Pfizer Strengthens Manufacturing Capabilities in Asia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children.
More Pharma News ...
- Data support Avandia (rosiglitazone maleate) cardiovascular safety profile
- Testing for Human Papillomavirus Genotypes 16 and 18 Detects Cervical Pre-Cancer Missed by Pap Test
- Lilly to Acquire Alnara Pharmaceuticals
- Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union
- AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research
- Expanding access to medicines for people living in the world's poorest countries
- Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System